The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Looks like people are beginning to realise its highly unlikely everything will fall into place this year now.
Wonder who next CEO will be and what options he gets, after the last farce
How true oneday nothing goes up in a straight line but this fell from 18p in a straight line
And its Aim some people are not as gullible nothing to do with deramping people should check peoples posting history on this share before following the leemings
Surginater . Thanks for that will be interesting to see what happens next few days
Take a few trades bigger than that to convince me.
I will average down on some confirmed assays not before and if you are right may not need to
GLA
Blantyreboy they have benb at it @ 3 years and best show was a misleading photo of a drill core they posted
with what they let people make assumptions it was gold. Board rampers went into over drive despite warnings.
Lot of PIs have lost confidence and a word of warning i would wait till you see confirmation.
No one is going to miss any boat.
"What makes you believe your comment 1day?
Why would I be buying on the lows if I didn't think it was going to reverse! WOW! "
Because you have called it all wrong for the last 2+ years and have been averaging sown all they way to here.
Even you must get the bottom the amount of times you have posted your buys on here.
As for the crazy traders they must of been nuts selling at !8p dont you feel silly for all the stick you gave then ?
Looks like that didnt have the desired effect imagine the mention of funding
put the cosh on it and will be a drag on sp ?
Financing required for Phase II
With projected net cash at £2.0m by end FY23 and an anticipated cash burn rate of £11.3m in FY24, we estimate that OCT has an immediate need to raise additional capital. We expect it to raise a total of £40m through FY26 (£15m in both FY24 and FY25, and £10m in FY26), which we have modelled as illustrative debt. Our model assumes that OCT will enter a global licensing deal in FY26 for both indications.